Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate safety and 2-year local control rate for extensive clinical target volumes in postoperative radiotherapy concurrent with chemotherapy for esophageal squamous cell carcinoma.

Conditions
-----------------
Esophageal Squamous Cell Carcinoma

Intervention / Treatment
-----------------
* Drug: Paclitaxel
* Drug: Carboplatin
* Radiation: Radiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Joined the study voluntarily and signed informed consent form; Age 18-75; ECOG 0-2; Esophageal squamous cell carcinoma, radical surgery ≤ 3 months, R0 resection; The operative incision healed well; T3-4N0M0, T1-4N1-3M0 (according to AJCC2009); No radiotherapy, chemotherapy or other treatments pre (post) surgery; PS ECOG 0-2; Life expectancy of more than 3 months; Hemoglobin (Hb) ≥ 9 g/dL • WBC ≥ 3 x 109/L, Neutrophils (ANC ) ≥ 1.5 x 109/L • platelet count (Pt) ≥ 100 x 109/L • Hepatic function: ALAT and ASAT < 2.5 x ULN, TBIL< 1.5 x ULN • Renal function: creatinine < 1.5 x ULN No immuno-deficiency; Use of an effective contraceptive for adults to prevent pregnancy. Exclusion Criteria: Complete esophageal obstruction after surgery, Esophageal perforation, Haematemesis; Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived with no evidence disease for over 3 years; Participation in other interventional clinical trials within 30 days; Pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives; Drug addiction, Alcoholism or AIDS; Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior; Unsuitable to be enrolled in the trial in the opinion of the investigators.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Chemo-radiation group<br>A total dose of 45Gy will be delivered in 25 fractions at 1.8Gy/fraction, 5 fractions per week in 5 weeks. The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and celiac nodes. Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw*5 | Drug: Paclitaxel<br>* paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw*5<br>Drug: Carboplatin<br>* carboplatin AUC=2, ivgtt, d1, qw*5<br>Radiation: Radiotherapy<br>* 1.8Gy/d, d1-5/week, 25Fx<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Local control rate |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival |  | 5 years |